Меню
Набор скоро начнётся NCT07536178

Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada

Без фазы С лечением Asthma Chronic Obstructive Pulmonary Disease (COPD) Lung Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Woodsmoke (Lodgepole Pine) exposure, Filtered air exposure.
Кому может быть актуально
Состояния в реестре: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Lung Cancer. Базовые параметры: 19 лет — 80 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

Wildfire smoke (WFS) is the leading climate-related risk in Canada and the main source of harmful air pollution. While short-term breathing problems caused by smoke are well known, there is limited knowledge on how repeated exposure contributes to long-term lung disease. This study is a controlled human exposure to varying concentrations of WFS in a safe setting. By comparing the effects of different concentrations, this research will improve understanding of health impacts, identify who may be most vulnerable to exposures, and explore biological changes that could lead to chronic illness.

Подробное описание

PURPOSE: To use responses to controlled human exposures to woodsmoke, as a model of wildfire smoke (WFS), to quantify risk of, and add biological plausibility to, the supposition that WFS-related particulate matter with a diameter of 2.5 micrometers or less (PM2.5) contributes to the development of neurological and chronic lung diseases.

Study Exposure Arms:

Arm A: 3 consecutive days with 2h woodsmoke exposures at 35 µg/m3 of PM2.5 Arm B: 3 consecutive days with 2h woodsmoke exposures at 105 µg/m3 of PM2.5 Arm C: 2 consecutive days of Filtered Air (FA), followed by 1 day with a 2h woodsmoke exposure at 315 µg/m3 of PM2.5

HYPOTHESIS, JUSTIFICATIONS, AND OBJECTIVES Aim 1A: Enhance plausibility for, and quantify risk of, WFS contributions to chronic lung disease.

Hypothesis 1A: The investigators will determine mechanisms that plausibly link WFS exposure to the development of chronic disease, by connecting WFS exposures to lung function decline, asthma, chronic obstructive pulmonary disease (COPD), or lung cancer.

To assess the plausibility of linking WFS exposure to Chronic Lung Diseases such as asthma, COPD, and lung cancer.

To evaluate the biological impacts of WFS on the airways.

* Specifically, what are the effects of exposure concentration, intensity, and time on inflammatory and immunomodulatory responses to WFS exposure? * Several biological pathways may link WFS exposures with the development of chronic respiratory diseases such as asthma, COPD, and lung cancer. These include effects of oxidative stress and inflammation on epithelial barrier integrity, which may facilitate contact with immune cells, allergen sensitization, increased infection susceptibility, and tissue remodelling that impairs lung function. Epigenetics, notably DNA methylation (DNAm), is another potential mechanism linking WFS to chronic disease, and the airway microbiome may also contribute through several pathways. However, WFS differs from general urban and traffic-related air pollution (TRAP), so effects of TRAP exposure demonstrated to date cannot be assumed to apply to WFS.

Aim 1B: Use a controlled human exposure study to identify, across different intensities of WFS exposure:

1.1 Neurocognitive changes relevant to the development of chronic neurological diseases 1.2 Temporal patterns of onset and resolution in relevant circulating neuro-inflammatory markers 1.3 Sex, age, and genetics as effect-modifying susceptibility factors for the above phenomena

Hypothesis 1B: The investigators will demonstrate disturbances in the brain default mode network (DMN), and intensity-dependent increases in circulating neuro-inflammatory markers, particularly in older individuals and those with genotypes conferring deficient anti-oxidant metabolism or those conferring risk of dementia.

RESEARCH DESIGN A randomized, double-blinded, crossover-controlled human exposure study.

STATISTICAL ANALYSIS Data will be analysed in R using generalized and linear mixed-effects models. Models will run with exposure as a fixed effect and participant ID as a random effect.

Вмешательства

  • Другое Woodsmoke (Lodgepole Pine) exposure
    Woodsmoke will be freshly generated using a furnace tube burning dried, ground lodgepole pine (Pinus contorta) to achieve the nominal PM2.5 (particulate matter with an aerodynamic diameter of less than or equal to 2.5 micrometres) concentrations specified for each study arm.
  • Другое Filtered air exposure
    Exposures to HEPA filtered air, as a control.

Первичные конечные точки

  • Effects of PM2.5 exposures and concentration on exhaled nitric oxide. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on Cambridge Neuropsychological Test Automated Battery (CANTAB) [Срок оценки: Comparison of the different arms over the span of 4 months.]
Вторичные конечные точки (10)
  • Effects of PM2.5 exposures and concentration on sputum cell numbers. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on brain functional connectivity. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on oxidative stress. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on lung inflammatory markers. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on lung imaging. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on circulating brain-derived biomarkers of neuroinflammation. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on neutrophil extracellular traps (NETs). [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on host defence proteins. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on DNA methylation. [Срок оценки: Comparison of the different arms over the span of 4 months.]
  • Effects of PM2.5 exposures and concentration on glia-derived extracellular vesicles. [Срок оценки: Comparison of the different arms over the span of 4 months.]

Критерии участия

Критерии включения

  • Healthy Adults between the ages of 19 to 80 (12 of each biological sex assigned at birth).

Критерии исключения

  • Current smoker (within six months before screening; potential to confound exposure effects).
  • History or current diagnosis of any respiratory conditions (including, but not limited to asthma or chronic obstructive pulmonary disease (COPD), asthma/COPD overlap) or other medical conditions that the study physician determines may impact participant safety.
  • Any comorbidities or other concerns identified by the study physician which may impact study participation.
  • For participants of child-bearing potential: Current pregnancy, or plans to become pregnant during study enrolment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Перекрёстный дизайн
Маскирование
Тройное слепое
Основная цель
Профилактика

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07536178 · H25-02833 · LG3-193738 · RFA 24-2

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗